The European Commission has launched a public consultation to gather views on the strengths and weaknesses of the European Medicines Agency’s system for collecting fees from the pharmaceutical industry for regulatory services and remunerating the regulators that perform those services.
Aimed at all relevant stakeholders, but particularly those with active experience of the fee system, such as the pharmaceutical industry, academia and research organizations, the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?